Drug Search Results
More Filters [+]

AG-013

Alternative Names: ag-013, ag013, ag 013
Latest Update: 2020-10-05
Latest Update Note: Clinical Trial Update

Product Description

AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis).

Mechanisms of Action: Angiogenesis Inhibitor,VEGFR Inhibitor

Novel Mechanism: No

Modality: Nondrug

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Oragenics
Company Location: TAMPA FL 33634
Company CEO: Kimberly Murphy
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AG-013

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mucositis|Stomatitis|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Colorectal Cancer

Phase 1: Head and Neck Cancer|Stomatitis|Mucositis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2016-004161-68

P2

Completed

Head and Neck Cancer|Mucositis

2020-07-02

AG013-ODOM-201

P2

Terminated

Stomatitis|Mucositis

2020-03-31

24%

SENSOR

P2

Completed

Non-Small-Cell Lung Cancer|Colorectal Cancer

2019-03-19

AG013-ODOM-101

P1

Completed

Mucositis|Stomatitis|Head and Neck Cancer

2012-09-01

Recent News Events